Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.

Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.

Vaccine. 2017 Sep 5;35(37):4990-4996. doi: 10.1016/j.vaccine.2017.07.070. Epub 2017 Aug 7.

PMID:
28797729
2.

Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.

Chen Z, Schneerson R, Lovchik JA, Dai Z, Kubler-Kielb J, Agulto L, Leppla SH, Purcell RH.

Clin Vaccine Immunol. 2015 Aug;22(8):902-8. doi: 10.1128/CVI.00137-15. Epub 2015 Jun 3.

3.

Toward a new vaccine for pertussis.

Robbins JB, Schneerson R, Kubler-Kielb J, Keith JM, Trollfors B, Vinogradov E, Shiloach J.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3213-6. doi: 10.1073/pnas.1324149111. Epub 2014 Feb 20.

4.

Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.

Thierry-Carstensen B, Dalby T, Stevner MA, Robbins JB, Schneerson R, Trollfors B.

Vaccine. 2013 Oct 25;31(45):5178-91. doi: 10.1016/j.vaccine.2013.08.034. Epub 2013 Aug 28. Review.

5.

Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen.

Keitel WA, Dai Z, Awe RW, Atmar RL, Morris S, Schneerson R, Robbins JB.

BMC Infect Dis. 2013 Jun 19;13:276. doi: 10.1186/1471-2334-13-276.

6.

A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.

Szu SC, Hunt S, Xie G, Robbins JB, Schneerson R, Gupta RK, Zhao Z, Tan X.

Vaccine. 2013 Apr 8;31(15):1970-4. doi: 10.1016/j.vaccine.2013.02.006. Epub 2013 Feb 17.

7.

The capsular polysaccharide and lipopolysaccharide structures of two carbapenem resistant Klebsiella pneumoniae outbreak isolates.

Kubler-Kielb J, Vinogradov E, Ng WI, Maczynska B, Junka A, Bartoszewicz M, Zelazny A, Bennett J, Schneerson R.

Carbohydr Res. 2013 Mar 22;369:6-9. doi: 10.1016/j.carres.2012.12.018. Epub 2012 Dec 29.

8.

Synthetic oligosaccharides as tools to demonstrate cross-reactivity between polysaccharide antigens.

Pozsgay V, Kubler-Kielb J, Coxon B, Santacroce P, Robbins JB, Schneerson R.

J Org Chem. 2012 Jul 20;77(14):5922-41. doi: 10.1021/jo300299p. Epub 2012 Jun 29.

9.

Measurement of Haemophilus influenzae type a capsular polysaccharide antibodies in cord blood sera.

Schmidt DS, Bieging KT, Gomez-de-León P, Villaseñor-Sierra A, Inostroza J, Robbins JB, Schneerson R, Carlone GM, Romero-Steiner S.

Pediatr Infect Dis J. 2012 Aug;31(8):876-8. doi: 10.1097/INF.0b013e31825ab166.

10.

Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R.

Clin Vaccine Immunol. 2012 Feb;19(2):140-5. doi: 10.1128/CVI.05556-11. Epub 2011 Dec 21.

11.

Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.

Robbins JB, Schneerson R, Xie G, Hanson LÅ, Miller MA.

Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):17871-5. doi: 10.1073/pnas.1114489108. Epub 2011 Oct 24. Erratum in: Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2684. Åke-Hanson, Lars [corrected to Hanson, Lars Å].

12.

Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections.

Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, Schneerson R, Robbins JB, Miller MA.

Clin Infect Dis. 2011 Nov;53(9):e117-24. doi: 10.1093/cid/cir500. Epub 2011 Sep 26.

13.

Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease.

Pozsgay V, Kubler-Kielb J, Coxon B, Marques A, Robbins JB, Schneerson R.

Carbohydr Res. 2011 Sep 6;346(12):1551-63. doi: 10.1016/j.carres.2011.04.045. Epub 2011 May 3.

14.

Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B Streptococcal disease.

Lin FY, Weisman LE, Azimi P, Young AE, Chang K, Cielo M, Moyer P, Troendle JF, Schneerson R, Robbins JB.

Pediatr Infect Dis J. 2011 Sep;30(9):759-63. doi: 10.1097/INF.0b013e31821dc76f.

15.

Specific Acquired Immunity.

Robbins JB, Schneerson R, Szu SC.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 8.

16.

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.

Thiem VD, Lin FY, Canh DG, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Schneerson R, Szu SC.

Clin Vaccine Immunol. 2011 May;18(5):730-5. doi: 10.1128/CVI.00532-10. Epub 2011 Mar 16.

17.

Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine.

Kubler-Kielb J, Vinogradov E, Lagergård T, Ginzberg A, King JD, Preston A, Maskell DJ, Pozsgay V, Keith JM, Robbins JB, Schneerson R.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4087-92. doi: 10.1073/pnas.1100782108. Epub 2011 Feb 22.

18.

Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Chen Z, Schneerson R, Lovchik J, Lyons CR, Zhao H, Dai Z, Kubler-Kielb J, Leppla SH, Purcell RH.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):739-44. doi: 10.1073/pnas.1017677108. Epub 2010 Dec 27.

19.

Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.

Rouphael NG, Satola S, Farley MM, Rudolph K, Schmidt DS, Gomez-de-León P, Robbins JB, Schneerson R, Carlone GM, Romero-Steiner S.

Clin Vaccine Immunol. 2011 Feb;18(2):243-7. doi: 10.1128/CVI.00219-10. Epub 2010 Dec 22.

20.

The structure of the Escherichia coli O148 lipopolysaccharide core region and its linkage to the O-specific polysaccharide.

Kubler-Kielb J, Lai WT, Schneerson R, Vinogradov E.

Carbohydr Res. 2011 Jan 3;346(1):150-2. doi: 10.1016/j.carres.2010.10.012. Epub 2010 Oct 20.

21.

Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates.

Kubler-Kielb J, Vinogradov E, Mocca C, Pozsgay V, Coxon B, Robbins JB, Schneerson R.

Carbohydr Res. 2010 Jul 19;345(11):1600-8. doi: 10.1016/j.carres.2010.05.006. Epub 2010 May 15.

22.

A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.

Kubler-Kielb J, Majadly F, Biesova Z, Mocca CP, Guo C, Nussenzweig R, Nussenzweig V, Mishra S, Wu Y, Miller LH, Keith JM, Liu TY, Robbins JB, Schneerson R.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1172-7. doi: 10.1073/pnas.0913374107. Epub 2009 Dec 28.

23.

Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.

Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R; Israeli Shigella Study Group.

Vaccine. 2010 Mar 2;28(10):2231-5. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5.

24.

Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.

Biesova Z, Miller MA, Schneerson R, Shiloach J, Green KY, Robbins JB, Keith JM.

Vaccine. 2009 Oct 19;27(44):6234-8. doi: 10.1016/j.vaccine.2009.07.107. Epub 2009 Aug 15.

25.

Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates.

Robbins JB, Kubler-Kielb J, Vinogradov E, Mocca C, Pozsgay V, Shiloach J, Schneerson R.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7974-8. doi: 10.1073/pnas.0900891106. Epub 2009 Apr 3.

26.

Risk of adverse birth outcome after group B meningococcal disease: results from a Danish national cohort.

Howitz MF, Simonsen J, Krause TG, Robbins JB, Schneerson R, Mølbak K, Miller MA.

Pediatr Infect Dis J. 2009 Mar;28(3):199-203. doi: 10.1097/INF.0b013e31818c9049.

PMID:
19165135
27.

Pertussis vaccine: a critique.

Robbins JB, Schneerson R, Keith JM, Miller MA, Kubler-Kielb J, Trollfors B.

Pediatr Infect Dis J. 2009 Mar;28(3):237-41. doi: 10.1097/INF.0b013e31818a8958.

28.

The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain.

Kubler-Kielb J, Schneerson R, Mocca C, Vinogradov E.

Carbohydr Res. 2008 Dec 8;343(18):3123-7. doi: 10.1016/j.carres.2008.09.017. Epub 2008 Sep 24.

29.

Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.

Kubler-Kielb J, Vinogradov E, Hu H, Leppla SH, Robbins JB, Schneerson R.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8709-12. doi: 10.1073/pnas.0803897105. Epub 2008 Jun 18.

30.

Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Kubler-Kielb J, Vinogradov E, Ben-Menachem G, Pozsgay V, Robbins JB, Schneerson R.

Vaccine. 2008 Jul 4;26(29-30):3587-93. doi: 10.1016/j.vaccine.2008.04.079. Epub 2008 May 20.

31.

Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN.

Vaccine. 2008 Feb 13;26(7):869-73. doi: 10.1016/j.vaccine.2007.11.085. Epub 2007 Dec 26.

32.

Lack of association between group B meningococcal disease and autoimmune disease.

Howitz M, Krause TG, Simonsen JB, Hoffmann S, Frisch M, Nielsen NM, Robbins J, Schneerson R, Mølbak K, Miller MA.

Clin Infect Dis. 2007 Nov 15;45(10):1327-34. Epub 2007 Oct 4.

PMID:
17968829
33.

Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.

Pozsgay V, Kubler-Kielb J, Schneerson R, Robbins JB.

Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14478-82. Epub 2007 Aug 28.

34.

Haemophilus influenzae type a infection and its prevention.

Jin Z, Romero-Steiner S, Carlone GM, Robbins JB, Schneerson R.

Infect Immun. 2007 Jun;75(6):2650-4. Epub 2007 Mar 12. Review. No abstract available.

35.

The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.

Robbins JB, Schneerson R, Keith JM, Shiloach J, Miller M, Trollors B.

Vaccine. 2007 Apr 12;25(15):2811-6. Epub 2006 Dec 21.

PMID:
17291636
36.

O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.

Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, Schneerson R, Robbins J, Passwell JH.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2396-401. Epub 2007 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2007 May 1;104(18):7729.

37.

Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB, Schneerson R.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):293-8. Epub 2006 Dec 26.

38.

O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a.

Kubler-Kielb J, Vinogradov E, Chu C, Schneerson R.

Carbohydr Res. 2007 Feb 26;342(3-4):643-7. Epub 2006 Nov 7.

39.

Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates.

Kubler-Kielb J, Liu TY, Mocca C, Majadly F, Robbins JB, Schneerson R.

Infect Immun. 2006 Aug;74(8):4744-9.

40.

Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates.

Fekete A, Hoogerhout P, Zomer G, Kubler-Kielb J, Schneerson R, Robbins JB, Pozsgay V.

Carbohydr Res. 2006 Sep 4;341(12):2037-48. Epub 2006 Feb 3.

PMID:
16458277
41.
42.

Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?

Stein DM, Robbins J, Miller MA, Lin FY, Schneerson R.

Vaccine. 2006 Jan 16;24(3):221-8. Epub 2005 Aug 11. Review.

PMID:
16125824
43.
44.

Future vaccine development at NICHD.

Robbins JB, Schneerson R.

Ann N Y Acad Sci. 2004 Dec;1038:49-59.

PMID:
15838097
45.

Surveillance for bacterial meningitis by means of polymerase chain reaction.

Robbins JB, Schneerson R, Gotschlich EC.

Clin Infect Dis. 2005 Jan 1;40(1):26-7. Epub 2004 Dec 8. No abstract available.

PMID:
15614688
46.

The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.

Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, Rappuoli R, Keith JM.

J Infect Dis. 2005 Jan 1;191(1):81-8. Epub 2004 Nov 30. Review.

PMID:
15593007
47.

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC.

Infect Immun. 2004 Nov;72(11):6586-8.

48.

Chemical structure, conjugation, and cross-reactivity of Bacillus pumilus Sh18 cell wall polysaccharide.

Kubler-Kielb J, Coxon B, Schneerson R.

J Bacteriol. 2004 Oct;186(20):6891-901.

49.

Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan.

Glatman-Freedman A, Casadevall A, Dai Z, Jacobs WR Jr, Li A, Morris SL, Navoa JA, Piperdi S, Robbins JB, Schneerson R, Schwebach JR, Shapiro M.

J Clin Microbiol. 2004 Jul;42(7):3225-31.

50.

Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.

Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A.

Am Heart J. 2004 Apr;147(4):593-8.

PMID:
15077073

Supplemental Content

Loading ...
Support Center